Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

Table 4

HIV-1 RNA suppression at week 48, by number of active NRTIs and baseline CD4 count.

	Darunavir/ritonavir; 800/100 mg once daily	Darunavir/ritonavir; 600/100 mg twice daily
HIV-1 RNA <50 copies/mL
Number of active NRTIs
0	6/7 (86%)	8/9 (89%)
1	30/34 (88%)	32/35 (91%)
≥2	64/85 (75%)	69/88 (78%)
HIV-1 RNA <400 copies/mL
Number of active NRTIs
0	6/7 (86%)	9/9 (100%)
1	31/34 (91%)	32/35 (91%)
≥2	64/85 (75%)	74/88 (84%)
HIV-1 RNA <50 copies/mL
Baseline CD4 count
<200 cells/µL	49/59 (83%)	41/54 (76%)
≥200 cells/µL	62/76 (82%)	68/83 (82%)
HIV-1 RNA <400 copies/mL
Baseline CD4 count
<200 cells/µL	51/59 (86%)	44/54 (82%)
≥200 cells/µL	67/76 (88%)	71/83 (86%)